Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Solar urticaria is a rare but debilitating disease that can severely impact the quality of life, restricting outdoor activities.Treatment, based on sun protection and anti-histaminic drugs, is efficacious in 2 patients out of 3. In refractory patients, photodesensitization or immunosuppressive treatments such as cyclosporin A can be proposed. As in idiopathic urticaria, intravenous immunoglobulins (IVIG)have been shown, in a retrospective study of 7 patients, to dramatically improve 71% of patients. In an open-label prospective multicenter study, we aim to demonstrate the efficacy of a single IVIG administration (2g/kg) in 10 patients affected with severe and refractory solar urticaria.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Besancon
• Collaborators: Ministry of Health, France; Saint-Louis Hospital, Paris, France
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin

Criteria

Inclusion Criteria:

• social insurance

• signed informed consent

• solar urticaria (SU) confirmed with photoexplorations

• SU involving the face or generalized to the whole body or accompanied with bronchospasm or triggered by artificial light or per annual SU

• SU with altered quality of life

• SU resistant to photoprotection

• SU resistant to the association of two different antihistaminics during 3 months

Exclusion Criteria:

• Pregnancy

• Heat triggered urticaria

• Contra-indications to IVIG